Brief: Maia Biotechnology Reports Data From Phase 2 Trial For Non-Small Cell Lung Cancer
11/04/2023 13:36
April 11 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY REPORTS POSITIVE TOPLINE DATA FROM PART
A
SAFETY LEAD-IN OF THIO-101 PHASE 2 TRIAL FOR NON-SMALL CELL LUNG
CANCER
* MAIA BIOTECHNOLOGY REPORTS POSITIVE TOPLINE DATA FROM PART
A
SAFETY LEAD-IN OF THIO-101 PHASE 2 TRIAL FOR NON-SMALL CELL LUNG
CANCER
* MAIA BIOTECHNOLOGY INC - COMMENCED RECRUITMENT IN PART B
RANDOMIZED EFFICACY/DOSE SELECTION
* MAIA BIOTECHNOLOGY - THIO, ADMINISTERED IN SEQUENTIAL
COMBINATION WITH REGENERON'S ANTI-PD-1 THERAPY, LIBTAYO, WERE
GENERALLY WELL-TOLERATED
* MAIA BIOTECHNOLOGY INC - NO DOSE-LIMITING TOXICITIES
(DLTS) OR
SIGNIFICANT TREATMENT-RELATED ADVERSE EVENTS WERE OBSERVED
Source text for Eikon: ID:nBwc7Ctqza
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale